Literature DB >> 26297111

Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.

Mariana Toricelli1, Fabiana H M Melo1,2, Giovani B Peres3, Débora C P Silva4, Miriam G Jasiulionis5.   

Abstract

Entities:  

Year:  2015        PMID: 26297111      PMCID: PMC4546186          DOI: 10.1186/s12943-015-0405-2

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


× No keyword cloud information.

Erratum

After publication of this study [1], we found out that we unfortunately sent two figures in duplicate. They are Fig. 4b NT and Fig. 6c NT [1]. It is important to emphasize that the results shown in the graphs are correct since they represent the mean of three independent biological assays, each of them made in technical triplicates. The photographs are only representative figures of three biological assays.
Fig. 4

PI3-K signaling pathway is involved in anoikis resistance phenotype conferred by Timp1. The MaGFP and MaT1S cell lines were treated overnight with PI3-K inhibitors, Wortmannin (a) or LY294002 (b), and their clonogenic capability was evaluated. c Melan-a melanocytes stably transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt activation was assessed by Western blotting. *p < 0.05, **p < 0.01, ****p < 0.0001

Fig. 6

PI3-K inhibition renders melanoma cells anoikis sensitive. The 4C11- and 4C11+ melanoma cell lines were maintained in suspension for 96 hours in the presence of Wortmannin (a and b, respectively) or LY294002 (c and d, respectively). After 96 hours, suspended cells were plated and after 5 days clonogenic capacity was analyzed. 4C11-: non-metastatic melanoma cells; 4C11+: metastatic melanoma cells; NT: non-treated; Wn: Wortmannin; LY: LY294002. *p < 0.05, **p < 0.01, ***p < 0.001

PI3-K signaling pathway is involved in anoikis resistance phenotype conferred by Timp1. The MaGFP and MaT1S cell lines were treated overnight with PI3-K inhibitors, Wortmannin (a) or LY294002 (b), and their clonogenic capability was evaluated. c Melan-a melanocytes stably transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt activation was assessed by Western blotting. *p < 0.05, **p < 0.01, ****p < 0.0001 PI3-K inhibition renders melanoma cells anoikis sensitive. The 4C11- and 4C11+ melanoma cell lines were maintained in suspension for 96 hours in the presence of Wortmannin (a and b, respectively) or LY294002 (c and d, respectively). After 96 hours, suspended cells were plated and after 5 days clonogenic capacity was analyzed. 4C11-: non-metastatic melanoma cells; 4C11+: metastatic melanoma cells; NT: non-treated; Wn: Wortmannin; LY: LY294002. *p < 0.05, **p < 0.01, ***p < 0.001
  1 in total

1.  Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.

Authors:  Mariana Toricelli; Fabiana H M Melo; Giovani B Peres; Débora C P Silva; Miriam G Jasiulionis
Journal:  Mol Cancer       Date:  2013-03-25       Impact factor: 27.401

  1 in total
  1 in total

Review 1.  The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain.

Authors:  Jennifer M Dewing; Roxana O Carare; Andrew J Lotery; J Arjuna Ratnayaka
Journal:  Cells       Date:  2019-12-21       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.